pharma · Unstable Angina Pectoris · Gastric Carcinoma · COLL
COLLEGIUM PHARMACEUTICAL
COLLEGIUM PHARMACEUTICAL, INC
COLLEGIUM PHARMACEUTICAL trial registry — 30 ClinicalTrials.gov studies with program phase, status, and indication context.
100 Technology Center Dr, Stoughton, Massachusetts 02072, US HQ
617 Employees
Public company Type
COLL · NYSE Ticker
Company details
- Status
- Public
- HQ
- 100 Technology Center Dr, Stoughton, Massachusetts 02072, US
- Employees
- 617
- Programs
- 29
- Drugs
- 48
- Patents
- 28
COLLEGIUM PHARMACEUTICAL clinical trials
Registry index of 30 ClinicalTrials.gov studies linked to COLLEGIUM PHARMACEUTICAL programs — each row shows trial ID, program name, phase, status, and indication.
COLLEGIUM PHARMACEUTICAL trial registry — 30 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for COLLEGIUM PHARMACEUTICAL.
-
DICES — Phase 3
Clinical update -
PREVENT-MINS — Phase 3
Clinical update -
PB_A&A-ASC-FISTULA_1 — Phase 3
Clinical update -
HYP-NOR — Phase 3
Clinical update -
CADET-PAD — Phase 3
Clinical update -
AERD-COV19 — Phase 3
Clinical update -
Qarziba 4.5 mg/mL concentrate for solution for infusion — Phase 3
Clinical update -
IRINOTECAN — Phase 3
Clinical update
Trial registry
-
CTIS ↗ -
CTIS ↗ -
CTIS ↗ - 2024-513141-37-00CTIS ↗
Qarziba 4.5 mg/mL concentrate for solution for infusion
Recurrent or progression of neuroblastoma or neuroblastoma or neuroblastoma refractory to first-line treatment.
-
CTIS ↗ -
CTIS ↗ -
CTIS ↗ - 2024-518898-34-00CTIS ↗
PB_A&A-ASC-FISTULA_1
Anal or recto-cutaneous or recto-vaginal Crohn-related fistula
-
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ - NCT05779059CT.gov ↗
De-escalation to ticagrelor 60 mg at day 30
Non ST Segment Elevation Acute Coronary Syndrome
-
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗